Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion

[1]  S. Nobusawa,et al.  SLC44A1–PRKCA fusion in papillary and rosette-forming glioneuronal tumors , 2016, Journal of Clinical Neuroscience.

[2]  Jeremy G. Jones,et al.  Papillary glioneuronal tumour , 2015, Radiopaedia.org.

[3]  D. Merico,et al.  BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Grajkowska,et al.  Papillary glioneuronal tumor with an unusual bilateral intraventricular localization. , 2015, Clinical Neuropathology.

[5]  D. Geng,et al.  Neuroradiological Features of Papillary Glioneuronal Tumor: A Study of 8 Cases , 2014, Journal of computer assisted tomography.

[6]  N. Lehman,et al.  Anaplastic papillary glioneuronal tumor with extraneural metastases. , 2014, Journal of neuropathology and experimental neurology.

[7]  T. Pietsch,et al.  FGFR1 N546K mutation in a case of papillary glioneuronal tumor (PGNT) , 2014, Acta Neuropathologica.

[8]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[9]  S. Al-Sarraj,et al.  Papillary glioneuronal tumour: a review of the literature with two illustrative cases , 2013, British journal of neurosurgery.

[10]  M. Rosenblum,et al.  Identification of a Novel, Recurrent SLC44A1‐PRKCA Fusion in Papillary Glioneuronal Tumor , 2013, Brain pathology.

[11]  M. Preusser,et al.  Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells , 2013, Acta Neuropathologica.

[12]  K. Chang,et al.  Papillary Glioneuronal Tumors: A Review of Clinicopathologic and Molecular Genetic Studies , 2011, The American journal of surgical pathology.

[13]  L. Garraway,et al.  Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. , 2011, The Journal of molecular diagnostics : JMD.

[14]  P. Opolon,et al.  The selective VEGFR1‐3 inhibitor axitinib (AG‐013736) shows antitumor activity in human neuroblastoma xenografts , 2011, International journal of cancer.

[15]  J. Biegel,et al.  Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. , 2010, Neuro-oncology.

[16]  Hanlee P. Ji,et al.  Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. , 2010, Cancer research.

[17]  Jing Ma,et al.  Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas , 2009, The Journal of pathology.

[18]  Omer Guzel,et al.  ISO 15189 accreditation: Requirements for quality and competence of medical laboratories, experience of a laboratory I. , 2009, Clinical biochemistry.

[19]  Gulderen Yanikkaya-Demirel,et al.  ISO 15189 accreditation: Requirements for quality and competence of medical laboratories, experience of a laboratory II. , 2009, Clinical biochemistry.

[20]  P. Chanson,et al.  Mutational status of EGFR, BRAF, PI3KCA and JAK2 genes in endocrine tumors , 2009, International journal of cancer.

[21]  J. Finlay,et al.  Aggressive variant of a papillary glioneuronal tumor. Report of 2 cases. , 2009, Journal of neurosurgery. Pediatrics.

[22]  David T. W. Jones,et al.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.

[23]  J. Pimentel,et al.  Genetic alterations in a papillary glioneuronal tumor. , 2008, Journal of neurosurgery. Pediatrics.

[24]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[25]  Carl T Wittwer,et al.  High-resolution DNA melting analysis for simple and efficient molecular diagnostics. , 2007, Pharmacogenomics.

[26]  M. Polivka,et al.  Papillary glioneuronal tumor: not always a benign tumor? , 2007, Clinical Neuropathology.

[27]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .

[28]  E. Taboada,et al.  Papillary glioneuronal tumor: a case report and review of the literature. , 2006, Human pathology.

[29]  D. Figarella-Branger,et al.  Papillary glioneuronal tumour: clinicopathological and biochemical study of one case with 7-year follow up , 2000, Acta Neuropathologica.

[30]  C. Elger,et al.  The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies , 1999, Acta Neuropathologica.

[31]  R. McLendon,et al.  Papillary glioneuronal tumor: a new variant of mixed neuronal-glial neoplasm. , 1998, The American journal of surgical pathology.

[32]  F. Sanger,et al.  Nucleotide sequence of bacteriophage φX174 DNA , 1977, Nature.

[33]  F. Sanger,et al.  Nucleotide sequence of bacteriophage phi X174 DNA. , 1977, Nature.